Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9

American Journal of Pathology

Volumn 182, Issue 3, 2013, Pages 954-964

  Dong, Qian Ze ^a   Wang, Yang ^a   Tang, Zhong Ping ^a   Fu, Lin ^a   Li, Qing Chang ^a   Wang, En Di ^b   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CELL PROTEIN; DERLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANCHORAGE DEPENDENT GROWTH; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CELL GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; UPREGULATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROPORTIONAL HAZARDS MODELS; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; UP-REGULATION;

EID: 84874510030     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.11.019     Document Type: Article

References (45)

1. W.D. Travis Pathology of lung cancer Clin Chest Med 23 2002 65 81 viii
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
3. J.D. Minna, J.A. Roth, and A.F. Gazdar Focus on lung cancer Cancer Cell 1 2002 49 52
4. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu, and D.H. Johnson Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
5. H.Y. Chen, S.L. Yu, C.H. Chen, G.C. Chang, C.Y. Chen, A. Yuan, C.L. Cheng, C.H. Wang, H.J. Terng, S.F. Kao, W.K. Chan, H.N. Li, C.C. Liu, S. Singh, W.J. Chen, J.J. Chen, and P.C. Yang A five-gene signature and clinical outcome in non-small-cell lung cancer N Engl J Med 356 2007 11 20
6. D. O'Mahony, S. Kummar, and M.E. Gutierrez Non-small-cell lung cancer vaccine therapy: a concise review J Clin Oncol 23 2005 9022 9028
7. B.N. Lilley, and H.L. Ploegh A membrane protein required for dislocation of misfolded proteins from the ER Nature 429 2004 834 840
8. Y. Ye, Y. Shibata, C. Yun, D. Ron, and T.A. Rapoport A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol Nature 429 2004 841 847
9. F. Sun, R. Zhang, X. Gong, X. Geng, P.F. Drain, and R.A. Frizzell Derlin-1 promotes the efficient degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR folding mutants J Biol Chem 281 2006 36856 36863
10. J. Wang, H. Hua, Y. Ran, H. Zhang, W. Liu, Z. Yang, and Y. Jiang Derlin-1 is overexpressed in human breast carcinoma and protects cancer cells from endoplasmic reticulum stress-induced apoptosis Breast Cancer Res 10 2008 R7
11. A. Mori, S. Yamashita, K. Uchino, T. Suga, T. Ikeda, K. Takamatsu, M. Ishizaki, T. Koide, E. Kimura, S. Mita, Y. Maeda, T. Hirano, and M. Uchino Derlin-1 overexpression ameliorates mutant SOD1-induced endoplasmic reticulum stress by reducing mutant SOD1 accumulation Neurochem Int 58 2011 344 353
12. Y. Ran, H. Hu, D. Hu, Z. Zhou, Y. Sun, L. Yu, L. Sun, J. Pan, J. Liu, T. Liu, and Z. Yang Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy Clin Cancer Res 14 2008 6538 6545
13. R. Klopfleisch, M. Schütze, H. Linzmann, L. Brunnberg, and A.D. Gruber Increased Derlin-1 expression in metastases of canine mammary adenocarcinomas J Comp Pathol 142 2010 79 83
14. E. Genersch, K. Hayess, Y. Neuenfeld, and H. Haller Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways J Cell Sci 113 Pt 23 2000 4319 4330
15. J. Yao, S. Xiong, K. Klos, N. Nguyen, R. Grijalva, P. Li, and D. Yu Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells Oncogene 20 2001 8066 8074
16. H.J. Byun, I.K. Hong, E. Kim, Y.J. Jin, D.I. Jeoung, J.H. Hahn, Y.M. Kim, S.H. Park, and H. Lee A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways J Biol Chem 281 2006 34833 34847
17. L.W. Cheung, P.C. Leung, and A.S. Wong Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9 Cancer Res 66 2006 10902 10910
18. J.R. Grandis, S.D. Drenning, A. Chakraborty, M.Y. Zhou, Q. Zeng, A.S. Pitt, and D.J. Tweardy Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro J Clin Invest 102 1998 1385 1392
19. P.A. Janne, J.A. Engelman, and B.E. Johnson Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology J Clin Oncol 23 2005 3227 3234
20. M.L. Sos, S. Fischer, R. Ullrich, M. Peifer, J.M. Heuckmann, M. Koker, S. Heynck, I. Stuckrath, J. Weiss, F. Fischer, K. Michel, A. Goel, L. Regales, K.A. Politi, S. Perera, M. Getlik, L.C. Heukamp, S. Ansen, T. Zander, R. Beroukhim, H. Kashkar, K.M. Shokat, W.R. Sellers, D. Rauh, C. Orr, K.P. Hoeflich, L. Friedman, K.K. Wong, W. Pao, and R.K. Thomas Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer Proc Natl Acad Sci U S A 106 2009 18351 18356
21. D.A. Eberhard, B.E. Johnson, L.C. Amler, A.D. Goddard, S.L. Heldens, R.S. Herbst, W.L. Ince, P.A. Janne, T. Januario, D.H. Johnson, P. Klein, V.A. Miller, M.A. Ostland, D.A. Ramies, D. Sebisanovic, J.A. Stinson, Y.R. Zhang, S. Seshagiri, and K.J. Hillan Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
22. A.C. Borczuk, R.L. Toonkel, and C.A. Powell Genomics of lung cancer Proc Am Thorac Soc 6 2009 152 158
23. M. Sanchez-Cespedes Lung cancer biology: a genetic and genomic perspective Clin Transl Oncol 11 2009 263 269
24. L.A. Liotta, and W.G. Stetler-Stevenson Tumor invasion and metastasis: an imbalance of positive and negative regulation Cancer Res 51 Suppl 1991 5054s 5059s
25. M. Johnsen, L.R. Lund, J. Romer, K. Almholt, and K. Dano Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation Curr Opin Cell Biol 10 1998 667 671
26. K. Kessenbrock, V. Plaks, and Z. Werb Matrix metalloproteinases: regulators of the tumor microenvironment Cell 141 2010 52 67
27. M. Egeblad, and Z. Werb New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 2002 161 174
28. T. Iizasa, T. Fujisawa, M. Suzuki, S. Motohashi, K. Yasufuku, T. Yasukawa, M. Baba, and M. Shiba Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients Clin Cancer Res 5 1999 149 153
29. M. Shiraga, S. Yano, A. Yamamoto, H. Ogawa, H. Goto, T. Miki, K. Miki, H. Zhang, and S. Sone Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines Cancer Res 62 2002 5967 5973
30. S. Ylisirnio, M. Hoyhtya, and T. Turpeenniemi-Hujanen Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer-TIMP-1 as a prognostic marker Anticancer Res 20 2000 1311 1316
31. B. Passlick, W. Sienel, R. Seen-Hibler, W. Wockel, O. Thetter, W. Mutschler, and K. Pantel Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer Clin Cancer Res 6 2000 3944 3948
32. I. Sehgal, and T.C. Thompson Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines Mol Biol Cell 10 1999 407 416
33. U.M. Munoz-Najar, K.M. Neurath, F. Vumbaca, and K.P. Claffey Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation Oncogene 25 2006 2379 2392
34. R.R. Baruch, H. Melinscak, J. Lo, Y. Liu, O. Yeung, and R.A. Hurta Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation Cell Biol Int 25 2001 411 420
35. Y. Ward, W. Wang, E. Woodhouse, I. Linnoila, L. Liotta, and K. Kelly Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways Mol Cell Biol 21 2001 5958 5969
36. L.J. Xiao, P. Lin, F. Lin, X. Liu, W. Qin, H.F. Zou, L. Guo, W. Liu, S.J. Wang, and X.G. Yu ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion Int J Oncol 40 2012 1714 1724
37. G. Das, A. Shiras, K. Shanmuganandam, and P. Shastry Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells Mol Carcinog 50 2011 412 423
38. S. Chakraborti, M. Mandal, S. Das, A. Mandal, and T. Chakraborti Regulation of matrix metalloproteinases: an overview Mol Cell Biochem 253 2003 269 285
39. H.J. Cho, J.H. Kang, J.Y. Kwak, T.S. Lee, I.S. Lee, N.G. Park, H. Nakajima, J. Magae, and Y.C. Chang Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms Carcinogenesis 28 2007 1104 1110
40. J.H. Yen, V.P. Kocieda, H. Jing, and D. Ganea Prostaglandin E2 induces matrix metalloproteinase 9 expression in dendritic cells through two independent signaling pathways leading to activator protein 1 (AP-1) activation J Biol Chem 286 2011 38913 38923
41. J.V. Alvarez, H. Greulich, W.R. Sellers, M. Meyerson, and D.A. Frank Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor Cancer Res 66 2006 3162 3168
42. C.D. Andl, T. Mizushima, K. Oyama, M. Bowser, H. Nakagawa, and A.K. Rustgi EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes Am J Physiol Gastrointest Liver Physiol 287 2004 G1227 G1237
43. S. Ghosh, J.C. Strum, V.A. Sciorra, L. Daniel, and R.M. Bell Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid: phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells J Biol Chem 271 1996 8472 8480
44. R. Kajanne, P. Miettinen, A. Mehlem, S.K. Leivonen, M. Birrer, M. Foschi, V.M. Kahari, and S. Leppa EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways J Cell Physiol 212 2007 489 497
45. C. Arteaga Targeting HER1/EGFR: a molecular approach to cancer therapy Semin Oncol 30 Suppl 7 2003 3 14